Trial Profile
A Phase I Open Label Study of Continuous Oral Treatment With BIBF 1120 Together With Pemetrexed in Previously Treated Patients With Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jul 2014
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 Jul 2014 New trial record